Prot #P-106-001: Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients with Respiratory Viral Infections After Hematopoietic Cell Transplant

Project: Research project

Project Details

StatusActive
Effective start/end date1/22/211/22/24

Funding

  • Medpace Clinical Research LLC (Prot #P-106-001)
  • AlloVir, Inc (Prot #P-106-001)